CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

This trial is testing a personalized immune cell therapy (CAR-T cell therapy targeting a protein called CD19) for patients with relapsed or treatment-resistant B-cell blood cancers, including various types of lymphoma and chronic lymphocytic leukemia (CLL). Researchers want to know if this approach is safe and effective in a broader population than currently approved products. **You may be eligible if...** - You are 18 or older - You have relapsed or refractory B-cell lymphoma (any type), CLL, or SLL that has not responded to or progressed after two or more prior treatments - You cannot receive or do not qualify for currently approved CAR-T products - You have measurable disease on imaging and adequate organ function - You are not pregnant and agree to use effective contraception **You may NOT be eligible if...** - You are currently able to receive a commercially approved CD19 CAR-T therapy - You have a history of seizures, autoimmune brain disease, or severe neurological conditions - You have had a heart attack, heart failure (Class III/IV), or cardiac stent/angioplasty within 6 months - You have active hepatitis B, hepatitis C, or HIV - You are on high-dose steroids or systemic immunosuppressants - You have another active cancer requiring treatment Talk to your doctor to see if this trial is right for you.